Results 141 to 150 of about 847 (163)

Atogepant, the first oral preventive treatment for chronic migraine

The Lancet, 2023
Haanes, Kristian A., Edvinsson, Lars
openaire   +3 more sources

Phase Ib, Open-Label, Fixed-Sequence, Drug–Drug Interaction, Safety, and Tolerability Study Between Atogepant and Ubrogepant in Participants With a History of Migraine

Headache, 2023
Jessica Ailani, Andrew M Blumenfeld, Richard B. Lipton   +2 more
exaly  

Atogepant punktet bei chronischer Migräne

NeuroTransmitter, 2022
openaire   +1 more source

A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial

Clinical Pharmacology in Drug Development, 2021
Ramesh R Boinpally, Matthew Butler, Lisa Borbridge   +2 more
exaly  

Atogepant for the preventive treatment of chronic migraine

Medicom Conference Report EHC 2022, 2023
openaire   +1 more source

Atogepant Reduces Migraine Days Over Three Months

Neurology Today, 2021
openaire   +1 more source

Atogepant: Schnell wirksame Migräneprophylaxe

DNP – Die Neurologie & Psychiatrie
openaire   +1 more source

4CPS-044 Comparison of the effectiveness of atogepant combined with botulinum toxin versus atogepant monotherapy in the prevention of chronic migraine

Section 4: Clinical pharmacy services
R Redondo-Arranz, C Puivecino-Moreno, I Sanchez-Lobon, N Herrero-Muñoz, C Gil Moreno, EM Garcia-Rebolledo   +5 more
openaire   +1 more source

Rapid complete responses with atogepant

Medicom Conference Report EHC 2024
openaire   +1 more source

COMBINATION COMPRISING ATOGEPANT FOR TREATING MIGRAINE

2023
BOINPALLY RAMESH, TRUGMAN JOEL
openaire   +1 more source